These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 19741717

  • 1. Bevacizumab: a new hope?
    Madhusudhana KC, Newsom RS.
    Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract] [Full Text] [Related]

  • 2. Tachyphylaxis and bevacizumab.
    Avgikos KN, Horgan SE, Sivaraj RR, Hu K.
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract] [Full Text] [Related]

  • 3. Tachyphylaxis and bevacizumab.
    Ziemssen F, Neuhann IM, Voelker M.
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract] [Full Text] [Related]

  • 4. Bevacizumab tachyphylaxis.
    Falavarjani KG, Modarres M.
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract] [Full Text] [Related]

  • 5. Treatments for macular degeneration: summarising evidence using network meta-analysis.
    Fadda V, Maratea D, Trippoli S, Messori A.
    Br J Ophthalmol; 2011 Oct; 95(10):1476-7. PubMed ID: 21680571
    [No Abstract] [Full Text] [Related]

  • 6. Bevacizumab: a new way of doing business?
    Canning C, Lotery A.
    Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
    [Abstract] [Full Text] [Related]

  • 7. Comparing ranibizumab with bevacizumab.
    Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S.
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract] [Full Text] [Related]

  • 8. Microperimetric changes after intravitreal bevacizumab for exudative age-related macular degeneration.
    Rensch F, Jonas JB.
    Acta Ophthalmol; 2008 Sep; 86(6):696-7. PubMed ID: 18752522
    [No Abstract] [Full Text] [Related]

  • 9. New treatments for age-related macular degeneration.
    Avery RL.
    Lancet; 2007 Oct 27; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness.
    Brown G.
    Curr Opin Ophthalmol; 2008 May 27; 19(3):175-6. PubMed ID: 18408489
    [No Abstract] [Full Text] [Related]

  • 11. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM, Klein RB.
    Retina; 2007 May 27; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F, Eid Farah M, Melo GB.
    Acta Ophthalmol Scand; 2006 Oct 27; 84(5):713-4. PubMed ID: 16965511
    [No Abstract] [Full Text] [Related]

  • 13. CATT: Into the eye of a tiger.
    Sears J, Bena J, Singh AD.
    Br J Ophthalmol; 2011 Jun 27; 95(6):761. PubMed ID: 21602481
    [No Abstract] [Full Text] [Related]

  • 14. Avastin versus Lucentis: ethical issues.
    Wong HC.
    Retina; 2008 Jun 27; 28(7):1024-5; author reply 1025. PubMed ID: 18698312
    [No Abstract] [Full Text] [Related]

  • 15. [New drug treatment for age-related macular degeneration].
    Stefánsson E, la Cour M, Helgadóttir G, Sigurdsson H, Jónasson F.
    Laeknabladid; 2007 Apr 27; 93(4):299-301. PubMed ID: 17460341
    [Abstract] [Full Text] [Related]

  • 16. Avastin and new treatments for AMD: where are we?
    Freeman WR, Falkenstein I.
    Retina; 2006 Oct 27; 26(8):853-8. PubMed ID: 17031283
    [No Abstract] [Full Text] [Related]

  • 17. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
    Bopp S.
    Br J Ophthalmol; 2007 Oct 27; 91(10):1259-60. PubMed ID: 17895411
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.